Meeting Program

  • Thursday, November 7th, 2019
  • Auditorium, Hanyang Institute of Technology (HIT) center, Seoul



Opening & Welcome address

09:00-9:10 Opening remark
Chae-Ok Yun, Ph.D. (Chair of Conference Organizer, Hanyang University)
Welcome address
Woo-Seung Kim, Ph.D. (President, Hanyang University)
Welcome address
Su Jae Lee, Ph.D. (Head, Industry-University Cooperation Foundation Hanyang University)
AM SESSION I: Immunotherapy, Vaccination strategies Chair : Farzin Farzaneh, King’s College London
09:10-09:40 Cells, Genes, and Peptides for active immune therapy of cancer
Farzin Farzaneh, Ph.D. (King’s College London, UK)
09:40-10:10 Therapeutic Vaccines for Hypertension and life style related diseases
Hironori Nakagami, M.D., Ph.D. (Osaka University, Japan)
Oral Presentation
A personalised iPSC-derived whole tumor cell vaccine evokes effective immunoreaction for prevention of lung cancer development
Zhe Zhang (Zhengzhou University, China)
10:30-10:50 Coffee & Poster Viewing
AM SESSION II: Nonviral Vector-mediated Gene Therapy Chair : Jin-Ho Choy, Dankook University
10:50-11:20 Boron Delivery System for Neutron Capture Therapy
Hiroyuki Nakamura, Ph.D. (Tokyo Institute of Technology, Japan)
11:20-11:50 10B-molecular bomb entrained 2D nanostealth targets tumor cells and tissues needing boron neutron capture therapy (BNCT)
Jin-Ho Choy, Ph.D. (Dankook University, Korea)
11:50-12:20 Drug-loaded polymeric nanoparticles for gene and cell therapy
Won Jong Kim, Ph.D. (POSTECH, Korea)
Development of fluorescent dyes and labeling methods for biomolecules
(BioActs, Korea)
12:40-13:30 Lunch provided
PM SESSION I: Oncolytic Virotherapy I Chair : Chae-Ok Yun, Hanyang University
13:30-14:00 New strategies of improving intravenous delivery of oncolytic vaccinia virus for
cancer treatment
Yaohe Wang, M.D., Ph.D. (Queen Mary University of London, England)
14:00-14:30 Evolving lessons on nanomaterial-coated viral vectors for local and
systemic gene therapy
Chae-Ok Yun, Ph.D. (Hanyang University, GeneMedicine Inc., Korea)
14:30-15:00 Novel oncolytic vaccinia virus which expressing anti-PD1 and anti-CD137
Monoclonal Antibodies and its anti-cancer effect
Min Liang, Ph.D. (Shanghai University, China)
15:00-15:30 Next-generation oncolytic vaccinia virus vectors for cancer virotherapy
Takafumi Nakamura, Ph.D. (Tottori University, Japan)
15:30-15:50 Coffee & Poster Viewing
PM SESSION II: Cell Therapy Chair : Byung-Geon Rhee, SCM Lifescience Inc
15:50-16:20 Allogenic Single Cell derived Clonal Mesenchymal Stem Cell's Clinical Application
Byung-Geon Rhee, Ph.D. (SCM Lifescience Inc., Korea)
16:20-16:50 Discovery of a novel NK cell platform for adoptive cancer immunotherapy
with chimeric antigen receptors
Sae Won Kim, Ph.D. (SL Bigen, Inc., Korea)
16:50-17:20 Relapsed/Refractory Cancer Patients were Treated with Tumor-Specific T Cells
Xiao-Song Zhong, MD., Ph.D. (Beijing Shijitan Hospital, China)
17:20-17:25 Introduction to IOVC2020
Tomoki Todo, IOVC2020 Conference president
18:00-20:00 Welcome reception
  • Friday, November 8th, 2019
  • Auditorium, Hanyang Institute of Technology (HIT) center, Seoul
AM SESSION I: Oncolytic Virotherapy II Chair : Hideki Kasuya, Nagoya University
Plenary session
Phase II clinical results of oncolytic herpes virus G47△
Tomoki Todo, MD, Ph.D. (Tokyo University, Japan)
09:40-10:10 Molecular mechanism of new targeting is explored in colon rectal carcinoma
Wenlin Huang, MD. (Guangzhou Double Bioproducts Inc, Guangzhou,Guangdong, China )
10:10-10:40 Antitumor predictive factors associated with oncolyti virus C-REV (formally HF10)
Hideki Kasuya, MD, Ph.D. (Nagoya University Graduate School of Medicine, Japan)
10:40-11:00 Coffee & Poster Viewing
AM SESSION II: Clinical Development of Gene Therapy Chair : Paola Grandi, Cold Genesys
11:00-11:30 Collategen, HGF Plasmid DNA, as first approved gene therapy drug to treat
cardiovascular diseases
Ryuichi Morishita, M.D., Ph.D. (Osaka University, Japan)
11:30-12:00 Phase I clinical study targeted for mesothelioma by intrapleural administration
of adenoviruses expressing NK4 gene
Masatoshi Tagawa, M.D., Ph.D. (Chiba Cancer Center Research Institute , Japan)
12:00-12:30 CG0070, an Oncolytic Adenovirus, for BCG-Unresponsive Non-Muscle-Invasive Bladder
Cancer (NMIBC): 12 Month Follow-Up from a Multicenter Phase II Trial
Paola Grandi, Ph.D. (Cold Genesys, Inc., USA)
(GeneMedicine Inc., Korea)
12:50-13:30 Lunch provided
PM SESSION I: Gene Editing and Recent Emerging Technology Chair : Keisuke Nimura, Osaka University
13:30-14:00 Elucidating a mechanism for RNA splicing driving human prostate cancer
Keisuke Nimura, Ph.D. (Osaka University, Japan)
14:00-14:30 Genome editing using CRISPR and its therapeutic application
Sangsu Bae, Ph.D. (Hanyang University, Korea)
14:30-15:00 PI3K/AKT-mediated Upregulation of WDR5 Promotes Colorectal Cancer Metastasis
by Directly Targeting ZNF407
Xin Tan, Ph.D. (Sun Yat-sen Memorial Hospital, China)

Oral Presentation
A Virus-Infected, Reprogrammed Somatic cell-derived Tumor cell (VIReST) regime can
prevent initiation and progression of pancreatic cancer
Shuangshuang Lu, Ph.D. (Zhengzhou University, China)
15:20-15:40 Coffee & Poster Viewing
PM SESSION II: Nanomedicine Chair : Won Jong Kim, POSTECH
15:40-16:10 The cationic nanocarriers and their roles in the immune regulation
Xiawei Wei, Ph.D. (Sichuan University, China)
16:10-16:40 Polymeric micelle-based nanomedicines for treatment of cancer
Sa-Won Lee, Ph.D. (Samyang biopharma, Inc., Korea)

Oral Presentation
Nano or cell carrier mediates efficient systemic delivery of oncolytic adenovirus for cancer treatment
Arum Yoon, Ph.D. (Hanyang University, Korea)


17:10-17:40 Molecular Therapy in Asia: challenges and opportunities
Robert M Frederickson, Ph.D., (Editor in Molecular Therapy, USA)

Poster Award & Closing Remark

17:40-17:50 Poster Award
Chae-Ok Yun, Ph.D. (Chair of Conference Organizer), Won Jong Kim, Ph.D.
(Co-chair of Conference Organizer)
17:50-18:00 Closing Remark
Won Jong Kim, Ph.D. (Co-Chair of Conference Organizer)
18:30- Banquet